Showing results (51-60 of 79) with videos related to
Sort By:
Pageof 8
International Journal of Cardiology|April 19, 2022
Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCEStephen P Juraschek, Dan Wang, John W McEvoy, et al.Journal of Diabetes|July 2, 2020
Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trialHyunju Kim, Dan Wang, John Chalmers, et al.Diabetes, Obesity & Metabolism|February 19, 2021
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trialMin Jun, Katie Harris, Hiddo J L Heerspink, et al.Journal of Hypertension|February 8, 2017
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trialsEmily R Atkins, Yoichiro Hirakawa, Abdul Salam, et al.Hypertension (Dallas, Tex. : 1979)|December 21, 2018
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes MellitusToshiaki Ohkuma, Min Jun, Anthony Rodgers, et al.Journal of Hypertension|March 1, 2019
EPHA4 regulates vascular smooth muscle cell contractility and is a sex-specific hypertension risk gene in individuals with type 2 diabetesZeqin Zhang, Johanne Tremblay, John Raelson, et al.Diabetes Care|May 26, 2021
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE TrialTu N Nguyen, Katie Harris, Mark Woodward, et al.Diabetes Research and Clinical Practice|June 9, 2012
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetesSusan van Dieren, Andre P Kengne, John Chalmers, et al.BMJ Open Diabetes Research & Care|May 6, 2025
Relationship between time-varying achieved HbA<sub>1c</sub> and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE studyLeah E Cahill, Rachel A Warren, Samantha K Lavallée, et al.Journal of Hypertension|January 7, 2017
PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation studyPavel Hamet, Mounsif Haloui, François Harvey, et al.Pageof 8